These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 21515049)
1. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. Zapf CW; Bloom JD; McBean JL; Dushin RG; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Jun; 21(12):3627-31. PubMed ID: 21605975 [TBL] [Abstract][Full Text] [Related]
3. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites. Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066 [TBL] [Abstract][Full Text] [Related]
6. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703 [TBL] [Abstract][Full Text] [Related]
7. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of macbecin as an Hsp90 inhibitor. Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. Zapf CW; Bloom JD; Li Z; Dushin RG; Nittoli T; Otteng M; Nikitenko A; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Olland A; Johnson M; Levin JI Bioorg Med Chem Lett; 2011 Aug; 21(15):4602-7. PubMed ID: 21715165 [TBL] [Abstract][Full Text] [Related]
11. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486 [TBL] [Abstract][Full Text] [Related]
12. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents. Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
14. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277 [TBL] [Abstract][Full Text] [Related]
15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671 [TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591 [TBL] [Abstract][Full Text] [Related]
17. Purine-scaffold Hsp90 inhibitors. Chiosis G; Tao H IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735 [TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90: inhibitors in clinical trials. Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425 [No Abstract] [Full Text] [Related]
20. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90. Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]